TD Cowen analyst Boris Peaker reiterated an Outperform rating on UroGen Pharma (NASDAQ: URGN) and named it a Best Idea ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE